Showing results (431-440 of 630) with videos related to
Sort By:
Pageof 63
The British Journal of Dermatology|September 22, 2020
What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational studyJ I Silverberg, D Lei, M Yousaf, et al.The British Journal of Dermatology|October 1, 2020
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trialJ I Silverberg, D Toth, T Bieber, et al.Eclinicalmedicine|July 3, 2023
Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trialJonathan I Silverberg, Peter A Lio, Eric L Simpson, et al.Dermatology and Therapy|April 18, 2022
Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysisJonathan I Silverberg, H Chih-Ho Hong, Jacob P Thyssen, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|September 6, 2022
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitisAndrew Blauvelt, Leon Kircik, Kim A Papp, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|March 12, 2021
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B studyJ I Silverberg, A Pinter, A Alavi, et al.The Journal of Dermatological Treatment|December 11, 2024
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registryJonathan I Silverberg, Brian M Calimlim, Ayman Grada, et al.Dermatology (Basel, Switzerland)|December 11, 2023
Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic DermatitisJacob P Thyssen, Anthony Bewley, Sonja Ständer, et al.Acta Dermato-Venereologica|October 7, 2021
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic DermatitisJonathan I Silverberg, Eric L Simpson, Mark Boguniewicz, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2022
Pharmacology of orismilast, a potent and selective PDE4 inhibitorJonathan I Silverberg, Lars E French, Richard B Warren, et al.Pageof 63